Further studies are needed to elucidate whether GNMT could serve as a therapeutic agent or like a sensitizer for other molecular targeting agents. Insulinomas will be the most common ubiquitin conjugation functioning pancreatic neuroendocrine tumours having an annual incidence of 1 to five cases per million. Approximately 10% of the circumstances have distantmetastases at diagnosis, although they are usually benign solitary tumours. Based on theWorld Health Organization, the only criterion for malignancy may be the existence of metastases and malignant insulinomas are connected with a greater threat of recurrence and mortality. Autonomous creation of excessive amounts of insulin resulting in life threatening hypoglycemia is the classical feature of the condition. A 72 hour watched Posttranslational modification (PTM) fasting study showing hyperinsulinemia and multiple nonsuppressed C peptide levels throughout biochemically proven hypoglycemia could be the proposed diagnostic process, however, the majority of the patients experience hypoglycemia within the initial 24-hours. Surgery is the first choice of therapy for benign and malignant insulinomas. But, some malignant insulinomas might be unresectable and treatments are limited for these people. Diazoxide, beta blockers, diphenylhydantoin, and somatostatin analogues might be helpful medical treatment options in terms of hypoglycemia control. Endemic chemotherapy, radioembolization, chemoembolization, radiotherapy, and peptide receptor radionuclide therapy may be tried as antitumour solutions. Everolimus is one of the target of rapamycin inhibitors which will be increasingly used as a new class of agents for the therapy of PNETs. It’s thought to have effects on both tumour development and glycemic regulation for insulinomas. 2. Case A 61-year old girl with history of recurrent life-threatening hypoglycemic episodes was called to our hospital with the feeling of an insulinoma. She was living in a rural area and her medical history didn’t show any systemic disease and drug-use. Hypoglycemic episodes class II HDAC inhibitor were getting more frequent and severe by time and were reported to start last year before admission. Diagnostic work-up for the exclusion of other potential causes of hypoglycemia was accomplished at the heart which she was referred from. On admission, she was claimed to be on continuous intravenous dextrose infusion for the past two weeks for avoiding the life threatening episodes of hypoglycemia. Subsequent hospitalisation at our clinic, dextrose infusion was stopped and fifteen minutes after she presented with neurological symptoms of hypoglycemia.. Her parallel plasma glucose was 41mg/dL with inappropriately substantial plasma insulin and C peptide levels, 82. 2??IU/mL and 3. 02 pmol/L, respectively. The diagnosis was confirmed as endogenous autonomous hyperinsulinism and further investigation to find an insulinoma was started.